Editas Medicine Inc - Company Profile
Powered by 
All the data and insights you need on Editas Medicine Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Editas Medicine Inc Strategy Report
- Understand Editas Medicine Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Editas Medicine Inc (Editas Medicine), formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. Its pipeline of medicines is focusing for people living with serious diseases. The company works in collaboration with Allergan/ AbbVie Inc, BlueRock Therapeutics, AskBio, Bayer AG, The Broad Institute Inc, Massachusetts Institute of Technology, and others to discover and develop its pipeline products. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
11 Hurley St, Cambridge, Massachusetts, 02141-2110
Website
www.editasmedicine.com
Telephone
1 617 4019000
No of Employees
265
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EDIT (NASD)
Revenue (2022)
$78.1M
296.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
30.5%
(2022 vs 2021)
Market Cap*
$508.1M
Net Profit Margin (2022)
XYZ
82.5%
(2022 vs 2021)
* As of and is in US$
Editas Medicine Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| In Vivo Gene-Editing Medicines |
| Ex Vivo Medicines |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with Vertex Pharmaceuticals under which Vertex will secure a non-exclusive license for Cas9 for CASGEVY. |
| 2023 | Regulatory Approval | In October, the company announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to EDIT-301 to treat patients with severe sickle cell disease (SCD). |
| 2023 | Regulatory Approval | In April, the company announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to EDIT-301. |
Competitor Comparison
| Key Parameters | Editas Medicine Inc | Vertex Pharmaceuticals Inc | Sarepta Therapeutics Inc | Beam Therapeutics Inc | CRISPR Therapeutics AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Switzerland |
| City | Cambridge | Boston | Cambridge | Cambridge | Zug |
| State/Province | Massachusetts | Massachusetts | Massachusetts | Massachusetts | - |
| No. of Employees | 265 | 5,400 | 1,314 | 436 | 407 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Emma Reeve | Chairman | Executive Board | 2023 | - |
| Gilmore O’Neill | President; Chief Executive Officer; Director | Executive Board | 2022 | - |
| Erick J. Lucera | Executive Vice President; Chief Financial Officer | Senior Management | 2023 | - |
| Linea Aspesi | Chief People Officer; Executive Vice President | Senior Management | 2023 | - |
| Baisong Mei, M.D., Ph.D | Senior Vice President; Chief Medical Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward